Please join Dr. Trevor Brasel as he will present and take questions about his research titled "The “Early” Days of COVID: Fast-Paced Research for a Fast-Paced Disease".
Dr. Brasel is an Associate Professor in the Department of Microbiology & Immunology and a Study Director in the Institutional Office of Regulated Nonclinical Studies at the University of Texas Medical Branch in Galveston. His research focuses on the strategic planning and execution of preclinical studies that evaluate medical countermeasures (vaccines and therapeutics) toward licensure. Dr. Brasel’s primary interests lie in the implementation of quality systems and regulatory processes in BSL-3 and BSL-4 laboratories to advance product development. For the past 15 years, he has focused on vaccine and therapeutic development and testing against emerging infectious diseases and high consequence pathogens including Ebola and Marburg viruses and, in recent years, SARS-CoV-2. As a means to further advance the field of regulatory science in high biocontainment laboratories, Dr. Brasel is serving as co-Principal Investigator on a grant funded through the FDA entitled "Achieving Data Quality and Integrity in Maximum Containment Laboratories," now in its tenth year of funding. Dr. Brasel's ultimate goal is FDA approval of high-profile medical countermeasures specific for biodefense-related and emerging diseases.